DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for focal segmental glomerulosclerosis 7 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFocal segmental glomerulosclerosis 7 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for focal segmental glomerulosclerosis 7 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Focal segmental glomerulosclerosis (FSGS) is a histologic lesion primarily affecting podocytes, and a common cause of nephrotic syndromes manifested by heavy proteinuria, minimal hematuria and hypoalbuminuria. If left undiagnosed or untreated, FSGS progressively damages glomeruli, causing a fall in glomerular filtration rate, renal failure, and the need for renal replacement therapy. Prognosis is very heterogeneous. Important prognostic factors include age of onset, proteinuria at onset, plasma creatinine at biopsy, duration of treatment with corticosteroids, genetics, and histopathologic subtype. Genetic causes of FSGS are often underdiagnosed in India, and genetic analysis has implications for prognostication, therapy, transplantation, and preimplantation genetic diagnosis.
Multiple treatment options such as steroids have been tried, but most showed only partial response, increased relapses after completing the treatment course, and increased adverse effects due to prolonged use. The 2021 Chinese expert consensus on diagnosis and treatment of FSGS in adults aims to provide clinicians with a masterable and practical treatment plan, but no specific drug efficacy data from a controlled trial are reported in these abstracts. No concrete numbers for survival, response rates, or sample sizes are given in any of the three abstracts.
What is still missing is a randomised controlled trial that reports quantitative outcomes for any drug in FSGS, as well as systematic genetic stratification of patients to predict which treatments might work. The abstracts do not name any drug beyond corticosteroids and ACTH, and no efficacy claims can be made from the information provided.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Kidney International Reports · 2024 · 0 citations · open access
WCN24-281 A STUDY ON THE FACTORS AFFECTING OUTCOMES OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND THE IMPORTANCE OF GENETIC DIAGNOSTICS IN PREDICTING OUTCOMES
AbstractFocal segmental glomerulosclerosis(FSGS) is a histologic lesion primarily affecting podocytes. Age of onset, proteinuria at onset, plasma creatinine at biopsy, duration of treatment with corticosteroids, genetics and histopathologic subtype are important prognostic factors in determining the outcome of primary FSGS. Genetic causes of FSGS are often underdiagnosed in India. Genetic analysis in FSGS have implications on prognostication, therapy, transplantation and preimplantation genetic diagnosis.
Family Medicine and Primary Care Open Access · 2019 · 0 citations · open access
Focal Segmental Glomerulosclerosis and the Role of ACTH
AbstractFocal Segmental Glomerulosclerosis (FSGS) is one of the common causes of nephrotic syndromes, manifested by heavy proteinuria, minimal hematuria and hypoalbuminemia. If left undiagnosed or untreated, FSGS will progressively damage enough glomeruli to cause a fall in Glomerular Filtration Rate (GFR) producing renal failure and require renal replacement therapy. For this reason, early identification and treatment is warranted to delay disease progression. Multiple treatment options such as steroids have been tried but most of these treatments showed partial response, increased relapses after completing treatment course and increased adverse effects due to prolonged use.
[Expert consensus on diagnosis and treatment of focal segmental glomerulosclerosis in adults].
AbstractFocal segmental glomerular sclerosis (FSGS) is a clinicopathological syndrome. The prognosis of FSGS patients is very heterogeneous, urging for personalized therapy to improve the long-term prognosis of patients. It provides FSGS clinical diagnosis and treatment workers with a masterable and practical treatment plan to help clinicians further improve their comprehensive diagnosis and treatment capabilities and levels. This collaborative group compiles the Chinese FSGS diagnosis and treatment expert consensus.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
